Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Ap­pli­ca­tion Sub­mit­ted for Con­di­tion­al Mar­ket­ing Au­tho­ri­sa­tion of the Pro­tein-based COVID-19 Vac­cine Can­di­date Vid­pre­vtyn

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA), on which the Paul-Ehrlich-Institut is represented, started the evaluation procedure on 30 March 2022 for the conditional marketing authorisation application submitted by Sanofi Pasteur for the protein-based SARS-CoV-2 vaccine Vidprevtyn. The EMA began its rolling review on 20 July 2021.

Sanofi COVID-19 Vaccine Vidprevtyn (Source: vladimka production/shutterstock.com)

Vidprevtyn is – following the already authorised COVID-19 vaccine Nuvaxovid from Novavax – now the second protein-based COVID-19 vaccine candidate to start the EU authorisation procedure. It contains a cell culture-produced version of the SARS-CoV-2 spike protein and AS03, an adjuvant.

The evaluation will be completed using data from clinical trials with more than 10,000 adult volunteers in the US, Latin America, Africa, and Asia who had not previously received a COVID-19 vaccine or been infected with SARS-CoV-2. They received two doses of the protein-based vaccine candidate, each containing 10 μg of antigen, at an interval of 21 days. The antigen contained in the vaccine corresponds to the spike protein of the D614 wild-type virus.

Updated: 31.03.2022